Drug
Nerandomilast clinical trials
Also written JASCAYD® and BI 1015550.
- studies test it
- 35
- open now
- 6
- in phase 3
- 8
- first study started
- 2012
Keep track of what changes. Save the nerandomilast studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 23
- Phase 2
- 3
- Phase 3
- 8
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 2
Boehringer Ingelheim (33) · University of British Columbia (1) · Scleroderma Research Foundation, Inc. (1)
Often tested with
Tested in the same studies.
Pirfenidone (2) · Nintedanib (1) · Midazolam (1) · Moxifloxacin (1) · Itraconazole (1) · Carbamazepine (1) · Bosentan (1) · BI 101550 (1)
Studies
Open first, then newest update. How each study uses nerandomilast is read from its arms, and is right about nine times in ten.
Testing it · 35
- A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory MyopathiesNot yet recruitingPhase 3Boehringer IngelheimNCT07789015Written as Nerandomilast
- FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionRecruitingPhase 3Boehringer IngelheimNCT07540988Written as Nerandomilast
- A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)RecruitingPhase 3Boehringer IngelheimNCT07366034Written as Nerandomilast
- A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruitingPhase 3Boehringer IngelheimNCT07201922Written as Nerandomilast
- Platform Clinical Study for Conquering SclerodermaRecruitingPhase 2Scleroderma Research Foundation, Inc.NCT06195072Written as BI 1015550 (Nerandomilast)
- This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.Not yet recruitingPhase 4University of British ColumbiaNCT07570888Written as Nerandomilast 18 mg - adult formulation
- A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesActive, not recruitingPhase 3Boehringer IngelheimNCT06806592Written as Nerandomilast
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingPhase 3Boehringer IngelheimNCT06238622Written as Nerandomilast
- A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodCompletedPhase 2Boehringer IngelheimNCT06241560Written as BI 1015550
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)CompletedPhase 3Boehringer IngelheimNCT05321082Written as BI 1015550
- A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06624072Written as Nerandomilast 18 mg - adult formulation
- A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05428436Written as Reference (R)
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the BloodCompletedPhase 1Boehringer IngelheimNCT06070610Written as BI 1015550
- A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT06393127Written as Nerandomilast
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the BloodCompletedPhase 1Boehringer IngelheimNCT05550636Written as BI 1015550
- A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT06408870Written as BI 1015550
- A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese MenCompletedPhase 1Boehringer IngelheimNCT06139302Written as Nerandomilast
- A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06415045Written as BI 1015550
- This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.CompletedPhase 1Boehringer IngelheimNCT03542344Written as BI 1015550 6 mg
- A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT05633862Written as BI 1015550
Codes
What other systems call nerandomilast · ClinicalTrials.gg INT002017
- MeSH (NLM) C000727475nerandomilastConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I5DGT51IB8NERANDOMILASTConfirmed FDA, NLM
- NCI Thesaurus C203229NerandomilastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000727475 | nerandomilast | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I5DGT51IB8 | NERANDOMILAST | Confirmed FDA, NLM |
| NCI Thesaurus | C203229 | Nerandomilast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.